sitagliptin + metformin hydrochloride tzf 50 mg + 850 mg tabletki powlekane
tarchomińskie zakłady farmaceutyczne "polfa" s.a. - sitagliptini hydrochloridum monohydricum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
sitagliptin stada 100 mg tabletki powlekane
stada arzneimittel ag - sitagliptin hydrochloride monohydrate - tabletki powlekane - 100 mg
sitagliptin stada 50 mg tabletki powlekane
stada arzneimittel ag - sitagliptin hydrochloride monohydrate - tabletki powlekane - 50 mg
sitagliptin grindeks 50 mg tabletki powlekane
as grindeks - sitagliptin hydrochloride monohydrate - tabletki powlekane - 50 mg
sitagliptin grindeks 25 mg tabletki powlekane
as grindeks - sitagliptin hydrochloride monohydrate - tabletki powlekane - 25 mg
sitagliptin grindeks 100 mg tabletki powlekane
as grindeks - sitagliptin hydrochloride monohydrate - tabletki powlekane - 100 mg
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
sitagliptin bioton 50 mg tabletki powlekane
bioton s.a. - sitagliptin hydrochloride monohydrate - tabletki powlekane - 50 mg
sitagliptin +pharma 100 mg tabletki powlekane
+pharma arzneimittel gmbh - sitagliptinum - tabletki powlekane - 100 mg
sitagliptin +pharma 25 mg tabletki powlekane
+pharma arzneimittel gmbh - sitagliptinum - tabletki powlekane - 25 mg